Numerate is a preclinical stage company with a virtual medicinal chemistry platform that combines advances in machine learning and cloud computing with traditional medicinal chemistry to design novel drug candidates. Unlike structure-based approaches that rely on crystal structure data, Numerate’s in silico platform uses all relevant data (SAR, patents, phenotypic data, etc.) to design novel compounds in an iterative fashion. The platform is ideally suited to emerging targets where there is little known data or where traditional methods have had trouble generating chemical matter that meets all the criteria for a drug candidate. In addition to its internal pipeline, Numerate has established partnerships with the Gladstone Institute and Defense Threat Reduction Agency.
Other investors include Atlas Ventures and LanzaTech Ventures.